Carlson Capital’s Cytokinetics CYTK Stock Holding History

Carlson Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$791K	Buy	12,000 +3,000	+33%	+$229K	0.16%	67
2026 Q2	$767K	Hold	9,000	–	–	0.16%	59
2026 Q1	$593K	Buy	9,000 +3,400	+61%	+$216K	0.19%	60
2025 Q4	$356K	Buy	5,600 +900	+19%	+$56K	0.13%	65
2025 Q3	$258K	Sell	4,700 -15,800	-77%	-$651K	0.1%	57
2025 Q2	$677K	Buy	20,500 +13,000	+173%	+$452K	0.28%	36
2025 Q1	$301K	Buy	+7,500	New	+$345K	0.12%	38
2024 Q3	–	Sell	-38,200	Closed	-$2.07M	–	28
2024 Q2	$2.07M	Buy	38,200 +13,200	+53%	+$797K	0.32%	74
2024 Q1	$1.75M	Buy	+25,000	New	+$1.93M	0.14%	94

Other funds holding CYTK

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Carlson Capital's CYTK Position: Q3 2026 in Review

Carlson Capital increased its Cytokinetics (CYTK) stake by 33% in Q3 2026, buying an estimated $229K and bringing the position to 12,000 shares worth $791K. The position accounts for 0.16% of the portfolio, ranked #67.

Carlson Capital first reported a position in CYTK in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.07M in Q2 2024. 282 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

Carlson Capital held 12,000 shares of Cytokinetics worth $791K as of Q3 2026.
Carlson Capital bought 3,000 Cytokinetics shares in Q3 2026, an estimated $229K.
Cytokinetics made up 0.16% of Carlson Capital's portfolio in Q3 2026, its #67 holding.
Carlson Capital first reported a position in Cytokinetics in Q1 2024 and has held it in 9 quarters since.
Carlson Capital's Cytokinetics position peaked at $2.07M in Q2 2024.
282 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Carlson Capital's 13F filing for Q3 2026, filed 9 Nov 2026.